• Genoa in the News

Genoa Healthcare® featured in Chain Drug Review’s 2022 Industry Outlook

Jan 21st, 2022

Genoa Healthcare Chief Executive Officer Joe Douglas provides outlook for 2022

2022 will be another important year for the behavioral health community. The increase in mental illness and substance use disorder, along with the staffing challenges and shift to telehealth that we saw in 2021, will continue to impact the health care industry. Our pharmacy teams are prepared to step up with additional services that meet the changing needs of our partners and consumers.

Genoa Healthcare Chief Executive Officer Joe Douglas takes a look at the opportunities for expanded access to care in 2022 and provides an industry outlook in Chain Drug Review’s 2022 forecast. You can read the full article here or view it in Chain Drug Review’s recent issue.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help

By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...

  • Consumer Stories
  • People-first Pharmacy Care
For people in crisis, access to a safe place is critical

Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...

  • Consumer Stories
  • People-first Pharmacy Care
Genoa pharmacist saves the life of someone she’s never met

Having witnessed the effects of the opioid crisis in her community firsthand, Genoa Healthcare® Pharmacist Kristen Pyland had prepared for the day she’d need to rush into action to aid...

Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Brixadi®: 3 things to know about the buprenorphine treatment option

Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...